LLY vs VNDA

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...

Vanda Pharmaceuticals remains an extremely speculative investment, with its immense 10x growth potential within 3-5 years almost entirely reliant on the successful regulatory approval and robust commercialization of tradipitant for gastroparesis. No material updates on tradipitant's progress have emerged. While existing products provide some revenue, they are insufficient for 10x growth. The lack ...